

Inotersen sodium

Cat. No.:	HY-132608
CAS No.:	1432726-13-0
Molecular Weight:	7601
Target:	Transthyretin (TTR)
Pathway:	Neuronal Signaling
Storage:	-20°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Inotersen (sodium)

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (13.16 mM); Need ultrasonic)					
		Solvent Concentration	Mass			
	Preparing Stock Solutions			1 mg	5 mg	10 mg
		1 mM		0.1316 mL	0.6578 mL	1.3156 mL
		5 mM		0.0263 mL	0.1316 mL	0.2631 mL
	10 mM		0.0132 mL	0.0658 mL	0.1316 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (13.16 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	Inotersen (ISIS-420915) sodium is a 2'-O-methoxyethyl-modified antisense oligonucleotide. Inotersen sodium inhibits the production of transthyretin (TTR) protein by targeting the TTR RNA transcript and reduces the levels of the TTR transcript. Inotersen sodium can be used for the research of hereditary TTR amyloidosis polyneuropathy ^{[1][2][3]} .
In Vitro	Inotersen sodium (0.16-20 μM; 16 h) dose-dependently reduces TTR mRNA levels in HepG2 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Inotersen sodium (10-100 mg/kg; s.c. twice a week for 4 weeks) reduces the plasma TTR protein by >80% in transgenic mice bearing the Ile84Ser human TTR mutant ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ackermann EJ, et, al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. *Amyloid*. 2016 Sep;23(3):148-157.

[2]. Mathew V, et, al. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. *Drug Des Devel Ther*. 2019 May 6;13:1515-1525.

[3]. Benson MD, et, al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. *N Engl J Med*. 2018 Jul 5;379(1):22-31.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA